This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Avid Bioservices, Inc.
9/9/2024
Good day, and thank you for standing by. Welcome to the Abbott BioServices first quarter fiscal year 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To answer your question, please press star one again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker for today. Tim, please go ahead.
Thank you. Good afternoon, and thank you for joining us. On today's call, we have Nick Green, President and CEO, Dan Hart, Chief Financial Officer, and Matt Quitniak, AVID's Chief Commercial Officer. Today, we will be providing an overview of Avid Bioservices contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended July 31st, 2024. After our prepared remarks, we will welcome your questions. Before we begin, I'd like to caution that comments made during this conference call today, September 9th, 2024, will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. concerning the current belief of the company, which involves a number of assumptions, risks, and uncertainties. Actual results could differ from these statements and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all the company's filings with the Securities and Exchange Commission concerning these and other matters. Our earnings press release includes discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website, abbottbio.com. With that, I will turn the call over to Nick Green, Abbott's president and CEO.
Thank you, Tim, and thank you to everybody participating today via webcast. Building on the momentum from Q4 fiscal 25 is off to a good start, and we are delighted to be reporting what I can only describe as a solid first quarter. We are encouraged by the strong revenues and new business signings, which continue to build our backlog and improve our margins. Matt and I will provide additional details on business development and operations for the period, following an overview of our first quarter fiscal 25 financial results. And for that, I'll turn the call over to Dan.
You're reading a preview of the CDMO Q1 2025 earnings call.
Free account.